What is Your Layered Security Approach? A Look at Defense in Depth

Barry Turner, Technical Business Development Manager at Red Lion Controls, joined host Tyler Kern for a live discussion on secure remote access and the importance of companies developing solutions that ensure a higher frequency of cyberattacks doesn’t end in disaster.

“Red Lion has been doing remote access for quite some time,” Turner said. “We just came out with our new remote access platform. It’s an all-encompassing platform that allows our customers to build machines and industrial products and send those products out into the field. And, if they need to get access to those assets wherever they may land, to do troubleshooting, to do upgrades or be able to work with those pieces of equipment as if they were local, our platform makes that simple, easy and secure.”

Red Lion uses a defense-in-depth, layered approach to security. It’s a combination of things put together to make it more and more difficult for would-be hackers to get into an asset.

Today, it makes perfect sense to have access to remote assets and devices for various needs, from service and maintenance to software updates. But that access must be secure. Recent cyberattacks like the Colonial Pipeline attack illustrate the importance of such security measures.

With solutions like the ones provided by Red Lion Controls, obtaining a high level of security is easy.

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More